Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Amortizatization of Intangibles (2016 - 2023)

Seres Therapeutics' Amortizatization of Intangibles history spans 8 years, with the latest figure at $49000.0 for Q2 2023.

  • For Q2 2023, Amortizatization of Intangibles rose 120.94% year-over-year to $49000.0; the TTM value through Mar 2024 reached $49000.0, up 126.06%, while the annual FY2023 figure was $236000.0, 134.3% up from the prior year.
  • Amortizatization of Intangibles for Q2 2023 was $49000.0 at Seres Therapeutics, down from $187000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $1.6 million in Q4 2021 and bottomed at -$851000.0 in Q1 2021.
  • The 5-year median for Amortizatization of Intangibles is -$12000.0 (2022), against an average of -$87400.0.
  • The largest annual shift saw Amortizatization of Intangibles soared 466.67% in 2019 before it tumbled 17300.0% in 2021.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $85000.0 in 2019, then plummeted by 748.24% to -$551000.0 in 2020, then skyrocketed by 390.2% to $1.6 million in 2021, then tumbled by 100.75% to -$12000.0 in 2022, then soared by 508.33% to $49000.0 in 2023.
  • Per Business Quant, the three most recent readings for MCRB's Amortizatization of Intangibles are $49000.0 (Q2 2023), $187000.0 (Q1 2023), and -$12000.0 (Q4 2022).